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ABSTRACT
PDAC is one of the most heterogeneous cancers with low chemotherapeutic sensitivity due to a dense
stroma, a weak vasculature and significant biological aggressivity. In cancer, suppressive immune
checkpoints are often hyper-activated to ensure an effective evasion of tumor cells from immune
surveillance. These immune checkpoints include in part, the B7/butyrophilin-like receptors such as
butyrophilin sub-family 3A/CD277 receptors (BTN3A), the B and T lymphocyte attenuator (BTLA) belong-
ing to the B7-like receptors and the programmed death protein (PD-1) with its ligand PD-L1. We
evaluated the plasma level of these markers in 32 PDAC patients (learning cohort) by ad hoc developed
ELISA’s and showed that there are highly correlated. We used ROC curves and univariate analysis to
characterize their prognostic relevance in these patients and showed that their plasma level can serve as
survival predictor. Plasma level thresholds that correlate with less than six months survival were
established for sPD-1 (>8.6 ng/ml), sPD-L1 (>0.36 ng/ml), sBTLA (>1.91 ng/ml), sBTN3A1 (>6.98 ng/ml)
and pan-sBTN3A (>6.92 ng/ml). These thresholds were applied in independent validation cohort
composed by 27 new samples and could efficiently discriminate short versus long PDAC survivors.
Our study reveals that monitoring the concentration of soluble forms of inhibitory immune checkpoints
in plasma can help predict survival in PDAC patients and therefore improve their treatments.
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Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is a major pub-
lic health issue. It is predicted to reach the second leading
cause of cancer-related death in Western countries by 2030.1
Currently, surgery is the only chance for a prolonged survi-
val but, unfortunately, only less than 20% of the PDAC
patients are eligible. Despite the improvement in surgical
techniques, there has been no major breakthrough in the
therapeutic arsenal. In addition, PDAC is one of the most
heterogeneous cancers with low chemotherapeutic sensitivity
due to a dense desmoplastic stroma, a weak vasculature and
significant biological aggressivity. Still today, the prognosis
remains extremely dark with a 5-year survival rate around
7%.2 Inflammation and immune evasion are two major hall-
marks of cancer and are crucial steps for PDAC
progression.3 The immune checkpoint family, belonging to
the immunoglobulin superfamily refers to transmembrane
receptors and co-receptors involved in immune homeostasis
to potentiate inflammation, autoimmunity but also tumor
immunity.4,5 However, in cancer, suppressive immune
checkpoints are often hyper-activated to ensure an effective
evasion of tumor cells from immune surveillance.6 These
immune checkpoints include in part, the B7/butyrophilin-
like receptors such as butyrophilin sub-family 3A/CD277
receptors (BTN3A),7,8 the B and T lymphocyte attenuator
(BTLA) belonging to the B7-like receptors9,10 and the pro-
grammed death protein (PD-1) with its ligands PD-L1 and
PD-L2. PD-1/PD-L1 pathways blockade (e.g. Nivolumab,
Pembrolizumab) has been widely studied in solids tumors
and lymphomas and shows promising therapeutic effect
particularly in melanomas and non-small cell lung
cancer.11,12 However, their efficacy for other solid tumors
such as PDAC remains controversial.13 Other immune
checkpoints such as the BTN3A sub-family, who play an
important role in Vϒ9Vδ2 T-cells activation and regulation,
have been described as therapeutic targets in cancer. BTN3A
members have been recently shown to be prognostic factors
in solid cancers.8 On the other hand, the B and
T lymphocyte attenuator (BTLA) have been shown to inhibit
tumor-specific CD8 + T cell proliferation and their high
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expression correlates with a shorter survival in some solid
tumors mainly of the gastrointestinal tract including gastric
cancer.9,10 Despite considerable efforts, the complete role of
these molecules in cancer immunotherapy and the specific
role of soluble ectodomains of these receptors remain to be
elucidated. Recently, the plasmatic soluble forms of sPD-1
and sPD-L1 have been shown to negatively correlate with
survival in myeloma.14 In the present study, we use specific
antibodies to monitor the concentrations of soluble forms of
PD-1, PD-L1, BTN3A sub-family (BTN3A1 and pan-BTN3A)
and BTLA in plasma of PDAC patients, by ad hoc developed
ELISAs. We showed that high plasma levels of these immune
checkpoints correlate with poor outcome and can be used as
prognostic factors in pancreatic adenocarcinomas.
Results
PDAC patients
Between 2012 and 2016, blood samples of 59 PDAC patients
were collected. All patients were recruited under the Paoli-
Calmette Institute clinical trial NCT01692873 (https://clinical
trials.gov/show/NCT01692873) exclusively in case of pancreatic
ductal adenocarcinoma diagnosis. From these 59 patients,
a total of 32 randomized samples compose the learning cohort.
The overall survival median of this cohort is 6.9 months (95%
CI (4.4–10.19)) that is very close to the worldwide reference OS
median of between 6 and 8 months for this type of patients
under palliative chemotherapy.15 We split the learning cohort
into two subgroups according to the 6 months OS cut-off.
Patients who died of disease before six months were named
short-term survival patients (STS, n = 16) and those who died
after six months were named long-term survival patients (LTS,
n = 16). The threshold levels given by the ELISAs for each
tested biomarker were validated in independent validation
cohort composed by 27 PDAC patients. All the patient’s char-
acteristics are provided in Tables 1 and 2 for the learning and
validation cohort, respectively. Eighty-five percent of patients
(50/59) received palliative treatments consisting of gemcitabine
(n = 20), gemcitabine–capecitabine (GEMZAR®/XELODA®)
combination treatments (n = 2) or FOLFIRINOX combination
(n = 28).
The levels of sPD-1, sPD-l1, Pan-sBTN3A and sBTLA are
highly correlated in PDAC patients
In this study, five specific ELISA tests were utilized to measure
plasma levels of sPD-L1, sPD-1, Pan-sBTN3A, sBTN3A1 and
sBTLA. Median values were 8.93 ng/ml for sPD-1 (range 0 to
25 ng/ml), 0.44 ng/ml for sPD-L1 (range 0 to 1.23 ng/ml),
7.56 ng/ml for sBTN3A1 (range 0 to 20.41 ng/ml), 8.39 ng/ml
for pan-sBTN3A (range 0 to 24.33 ng/ml) and 2.22 ng/ml for
sBTLA (range 0 to 11.68 ng/ml). Note that 10/32 patients from
the learning cohort presented values below the limit of detec-
tion for sBTLA. As shown in Figure 1, there is a close correla-
tion in the levels of all immune checkpoint soluble forms. As
expected, the best correlation (rp = 0.93, p = 3.2 10
−14) is
observed between sBTN3A1 and the pan-sBTN3A levels. The
soluble forms of PD-1 and PD-L1 share a strong correlation
(rp = 0.68, p = 1.6 10
–5) as already shown in another study on
advanced pancreatic cancer patients.16 In all cases, we observed
positive correlation between all tested markers.
Plasma levels of sBTN3A1, pan-sBTN3A, sBTLA, sPD-1 and
sPD-L1 negatively correlate with overall survival in PDAC
patients
As previously shown, high expressions of PD-1 and PD-L1 are
associated with poor prognosis in various types of solid tumors
and lymphomas.12,14,17 Moreover, the soluble forms of these
factors have been associated with shorter outcome in many
types of solid tumors such as digestive solid tumors and lung
cancer.16,18,19 However, the association between shorter out-
come and high level of sPD-1 and sPD-L1 has been poorly
investigated in patients with pancreatic adenocarcinoma. In
order to correlate the levels of soluble forms of all immune
checkpoints investigated in this study with overall patient’s
survival, we first used the linear Pearson correlation model.
We observed that sPD-1 and sPD-L1 levels negatively correlate
with OS in advanced pancreatic cancer patients (Figure 2(a))
(rp = −0.56, p value < 0.0009 and rp = −0.6, p value = 0.0004,
Table 1. Clinical characteristics from learning cohort.
PDAC patients characteristics (learning cohort)
All
STS
(≤6mo)
LTS
(>6mo)
n 32 16 (50%) 16 (50%)
Sex Male 17 (53%) 9 (56%) 8 (50%)
Female 15 (47%) 7 (44%) 8 (50%)
Age Mean 65 68 63
(Min-Max) (48–84) (48–84) (50–81)
Other
Cancers No 30 (93%) 14 (87.5%) 16 (100%)
Yes 2 (7%) 2 (12.5%) 0 (0%)
Tumor
Location Head 16 (50%) 5 (31%) 11 (69%)
Body 7 (22%) 6 (37.5%) 1 (6%)
Tail 5 (15.5%) 3 (19%) 2 (12%)
Liver (met) 4 (12.5%) 2 (12.5%) 2 (12%)
Median overall
survival
(months) 6.9 2.5 20.1
T
Stage Tx 20 (62.5%) 12 (75%) 8 (50%)
T1 0 (0%) 0 (0%) 0 (0%)
T2 1 (3%) 0 (0%) 1 (6%)
T3 9 (28.5%) 3 (19%) 6 (38%)
T4 2 (6%) 1 (6%) 1 (6%)
N
Stage Nx 31 (97%) 15 (94%) 16 (100%)
N0 1 (3%) 1 (6%) 0 (0%)
N1 0 (0%) 0 (0%) 0 (0%)
M
Stage Mx 0 (0%) 0 (0%) 0 (%)
M0 12 (35.7%) 4 (25%) 8 (50%)
M1 20 (62.5%) 12 (75%) 8 (50%)
Tumor status
at Diagnosis Localized 0 (0%) 0 (0%) 0 (0%)
Locally advanced 12 (37.5%) 4 (25%) 8 (50%)
Metastastic 19 (59.5%) 11 (69%) 8 (50%)
Carcinomatosis 1 (3%) 1 (6%) 0 (0%)
Tobacco No 14 (44%) 8 (50%) 6 (37.5%)
Yes 12(37%) 4(25%) 8 (50%)
n.d. 6 (19%) 4 (25%) 2 (12.5%)
Diabetes No 10 (31%) 5 (31%) 5 (31%)
Yes 9 (28%) 4 (25%) 5 (31%)
n.d. 13 (41%) 7 (44%) 6 (38%)
CA19.9 (U/ml) Normal (<37U/
ml)
3 (9%) 1 (6%) 2 (13%)
Elevated(≥37U/
ml)
13 (41%) 4 (25%) 9 (56%)
n.d 16 (50%) 11 (69%) 5 (31%)
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respectively). Surprisingly, the same observation was made with
the pan-sBTN3A family, sBTN3A1 and BTLA (rp = −0.57,
p value = 0.0006; rp = −0.6, p value = 0.0003 and rp = −0.38,
p value = 0.03, respectively). We then applied a univariate cox
regression model, including other well-known prognostic fac-
tors such as CA19.9 plasma level. As shown in Figure 2(b), all
soluble immune checkpoint monitored in this study are pre-
dictive survival markers in PDAC patients.
Determination of the optimal cut-off for each marker to
classify short term versus long term PDAC survivors
We used ROC curve analysis20 to determine for each marker the
optimal cut-off that discriminates short-versus long-term survi-
vors. As shown in Figure 3 A-F (left panels), the optimal cut-off
sPD-1 is 8.6 ng/ml (AUC = 0.85, p value < 0.001), 0.36 ng/ml for
sPD-L1 (AUC = 0.89, p value < 0.001), 1.91 ng/ml for sBTLA
(AUC = 0.78, p value = 0.001), 6.98 ng/ml for sBTN3A1
(AUC = 0.918, p value < 0.001) and 6.92 ng/ml for pan-sBTN
3A (AUC = 0.922, p value < 0.001). The plasma levels of each
marker are plotted in the right panels for long term and short-
term survivors, the red dashed lines indicate the threshold level
of each marker. Note that soluble forms of PD-L1 and BTN3A1
share the most important predictive power.
Clinical characteristics of patients with high plasma
concentrations of immune checkpoints
We classified, for each marker tested, the patients with low
and high plasma levels for each immune checkpoint, using
cut-offs determined beforehand with ROC curves. We plotted
the overall survival for these patients by Kaplan Meier curves
(Figure 4). For each biomarker analyzed (panels A to E), we
observe strong significant differences in overall survival med-
ians between patients with plasma concentrations above and
under thresholds. As expected, the strongest difference in
overall survival was observed with sPD-L1 as marker.
Patients with high level of sPD-L1 (>0.36 ng/ml) have a med-
ian survival of 2.8 months compared to 20.8 months for
Table 2. Clinical characteristics from the validation cohort.
PDAC patient characteristics (validation cohort)
All
STS
(≤6mo)
LTS
(>6mo)
n 27 5 (18%) 22 (82%)
Sex Male 11 (40%) 0 (0%) 11 (50%)
Female 16 (60%) 5 (100%) 11 (50%)
Age Mean 68 70 67
(Min-Max) (47–86) (61–80) (47–86)
Other
Cancers No 26 (96%) 4 (80%) 22 (100%)
Yes 1 (4%) 1 (20%) 0 (0%)
Tumor
Location Head 17 (63%) 2 (40%) 16 (73%)
Body 2 (7%) 1 (20%) 1 (4%)
Tail 8 (30%) 2 (40%) 5 (23%)
Liver (met) 0 (0%) 0 (0%) 0 (0%)
Median overall
survival
(months) 14.5 4.2 17.7
T
Stage Tx 7 (26%) 2 (40%) 5 (23%)
T1 1 (4%) 0 (0%) 1 (4.5%)
T2 6 (22%) 0 (0%) 6 (27%)
T3 13 (48%) 3 (60%) 10 (45.5%)
T4 0 (0%) 0 (0%) 0 (0%)
N
Stage Nx 11(41%) 3(60%) 8(36%)
N0 5(18%) 0(0%) 5(23%)
N1 11(41%) 2(40%) 9(41%)
M
Stage Mx 0 (0%) 0 (0%) 0 (0%)
M0 17 (63%) 3 (60%) 14 (63.5%)
M1 10 (37%) 2(40%) 8 (36.5%)
Tumor status
at Diagnosis Localized 15
(55.5%)
2 (40%) 13 (59%)
Locally advanced 3 (11%) 2 (40%) 1 (4.5%)
Metastastic 8 (29.5%) 1 (20%) 7 (32%)
Carcinomatosis 1 (4%) 0 (0%) 1 (4.5%)
Tobacco No 20 (74%) 4 (80%) 16 (73%)
Yes 6 (22%) 0 (0%) 6 (27%)
n.d. 1 (4%) 1 (20%) 0 (0%)
Diabetes No 21(78%) 2 (40%) 19 (86.5%)
Yes 4(15%) 2 (40%) 2 (9%)
n.d. 2(7%) 1 (20%) 1 (4.5%)
CA19.9 (U/ml) Normal (<37U/
ml)
2 (7%) 0 (0%) 2 (9%)
Elevated (≥37U/
ml)
8 (30%) 1(20%) 7 (32%)
n.d 17 (63%) 4(80%) 13 (59%)
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Figure 1. Correlation between plasma sBTN3A levels (assessed with “pan-sBTN3A” ELISA or “sBTN3A1-specific” ELISA), sPD-1, sPD-L1 and sBTLA in PDAC patients
(learning cohort, n = 32). Data are shown in ng/ml. According to the Gaussian distribution of data, the correlation was established using the parametric Pearson
correlation coefficient (r).
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patients with low level of sPD-L1 (log-rank p value <0.0001).
The same observation was made for sBTN3A1 and pan-sBTN
3A (2.8 vs 20.0 months for sBTN3A1, log-rank p value <0.0001
and 2.5 vs 20.0 months for pan-sBTN3A, log-rank
p value < 0.0001). In the same way, patients with high level
of soluble PD-1 (>8.6 ng/ml) have an overall survival median
of 3.4 months versus 20.0 months for patients with low level
of PD-1 (log-rank p value = 0.0002). Concerning sBTLA,
patients with high level (>1.91 ng/ml) have an overall survival
median of 3.4 months versus 17.4 months for patients with
low level of sBTLA (log-rank p value = 0.0035).
Validation cohort
We used 27 independent blood samples from PDAC patients
in order to confirm the correlation levels between each mar-
ker tested. In this cohort, the median values were 8.02 ng/ml
for sPD-1 (range 2.07 to 25 ng/ml), 0.36 ng/ml for sPD-L1
(range 0.14 to 1.57 ng/ml), 5.63 ng/ml for sBTN3A1 (range 0
to 40 ng/ml), 6.49 ng/ml for pan-sBTN3A (range 0 to
36.29 ng/ml) and 1.99 ng/ml for sBTLA (range 0 to
19.15 ng/ml). As shown in Figure 5, all tested biomarkers
present a close and significant correlation between their plas-
matic levels. As expected, we found a significative anti-
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Figure 2. Correlation between plasma levels of immune checkpoints (sPD-1, sPD-L1, sBTLA, sBTN3A1and pan-sBTN3A) and PDAC patient overall survival. In Figure 2A,
a significant inverse correlation was found between sPD-1 (p < 1.10–4), sPD-L1 (p = 4.10–3), sBTN3A1 (p = 3.10–3), pan-sBTN3A (p = 6.10–4), sBTLA (p = 3.10–2) and
patient overall survival (OS). The correlation was established using the parametric Pearson correlation coefficient (r). In Figure 2B, the prognostic relevance of each
marker was assessed by a univariate survival analysis using the Cox regression model.
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correlation between survival and high expression level in
plasma for each marker (Figure 6). This emphasizes our pre-
vious observation made in the learning cohort (Figure 2(a)).
We next applied the previously determined threshold levels in
learning cohort by the ROC curves approach. As shown in
Figure 7, these thresholds can efficiently discriminate short
versus long-term PDAC survivors in the validation cohort.
Patients with a high level of sPD-1 (>8.6 ng/ml) have a median
survival of 6.98 compared to 19.82 months for patients with
low level of sPD-1 (log-rank p value = 3.10−3). Concerning
patients with high level of sPD-L1 (>0.36), their median
survival is 9.41 versus 19.87 months for patients with low
level of sPD-L1 (log-rank p value = 7.10−4). The same obser-
vation was made for sBTN3A1 and pan-sBTN3A (5.38 vs
19.82 months for sBTN3A1, log-rank p value < 1.10–4 and
6.16 vs 21.41 months for pan-sBTN3A, log-rank p value < 1.10-
–3). Finally, the same observation was made for sBTLA (8.27
vs 19.87 months, log-rank p value < 1.10–4).
Discussion
In the present study, we show that plasma levels of the soluble
forms of immune checkpoints PD-1, PD-L1, the BTN3A family
and BTLA are strongly correlated in pancreatic cancer patients.
This is strongly suggestive of a common origin and regulation
of these markers in the blood of patients with pancreatic
adenocarcinoma. We also found a negative correlation between
patients overall survival and plasma levels of each marker. We
used ROC curve and univariate cox regression analysis in the
learning cohort in order to characterize the prognostic rele-
vance of each marker in PDAC patients. Thresholds were
established for sPD-1 (>8.6 ng/ml), sPD-L1 (>0.36 ng/ml),
sBTLA (>1.91 ng/ml), sBTN3A1 (>6.98 ng/ml) and pan-sBTN
3A (>6.92 ng/ml). These thresholds were validated in an inde-
pendent cohort of 27 blood samples from PDAC patients and
could efficiently discriminate short versus long-term survivors.
All patients with very short overall survival show plasma levels
above thresholds, as presented in Figures 3 and 4 (learning
cohort) and Figure 7 (validation cohort).
The PD-1/PD-L1 axis blockade showed encouraging results
in phase II/III clinical trials11,12,21 for treatment of several
solid tumors. However, the efficacy of such treatment (alone
or in combination) in patients with pancreatic tumors is quite
limited.21–24 Currently, only one study has monitored the
concentrations of soluble forms of sPD-1 and sPD-L1 in
advanced pancreatic cancer.16 The authors observe significant
correlations between the two concentrations but, in contra-
diction to our study, report no prognostic relevance of these
markers in patients with non-resectable pancreatic cancer.
Such discrepancy suggests that the choice of the study
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Figure 3. Receiver operating characteristics (ROC) curve analysis of plasma level for sPD-1, sPD-L1, sBTN3A1, pan-sBTN3A and sBTLA. For each marker, ROC curves
were plotted for sensitivity and specificity of survival classification (left panels). The yellow circle shows the optimal values of specificity and sensitivity for optimal
threshold values (Youden index associated criteria). The plasma levels of each marker were plotted for STS and LTS patients (right panels). The red dashed lines
represent the optimal thresholds obtained by ROC analysis. (AUC: area under the curve).
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model and of the methodology employed is critical. In this
study, we chose to detect soluble markers in plasma instead of
serum because levels detected in serum are 10 times lower
than in plasma from the same blood sampling, as described in
the Material and Methods section. In addition, some factors
might interfere with the determination of the concentration of
these factors.25,26 Despite a recent meta-analysis showing that
sPD-L1 is an adverse outcome prognostic marker either in
serum or plasma fraction of patients with diverse solid
tumors,17 we presume that test performed on plasma are
more reliable than in serum. Proteins from the butyrophilin
3A subfamily are promising stress-regulated markers recently
described in pancreatic cancer immune surveillance. The
BTN3A isoforms are overexpressed in pancreatic tumors
and involved in the antitumor function of Vγ9Vδ2 cytolytic
T-cells.7 The increases in BTN3A transcript levels are corre-
lated with increased concentrations in plasma of the soluble
forms of these markers release of soluble forms being appar-
ently triggered by metalloproteinase cleavage. In this work we
demonstrated that the concentration of soluble BTN3A is
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Figure 5. Correlation between plasma sBTN3A levels (assessed with “pan-sBTN3A” ELISA or “sBTN3A1-specific” ELISA), sPD-1, sPD-L1 and sBTLA in PDAC patients from
the validation cohort (n = 27).
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Figure 4. Kaplan Meier analysis of overall survival in patients from learning cohort with high and low plasma levels of sPD-1 (a), sPD-L1 (b), sBTLA (c), sBTN3A1 (d)
and pan-sBTN3A (e).
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higher in patients with pancreatic cancer than in those with
chronic calcifying pancreatitis or intraductal papillary muci-
nous neoplasms, suggesting that the soluble forms of pan-
BTN3A and the specific BTN3A1 isoform are prognostic
markers in patients with pancreatic cancer. The B and
T lymphocyte attenuator (BTLA/CD272) belongs to the
CD28 Ig superfamily and is a type I transmembrane co-
signaling receptor.27 This molecule is expressed at high level
in resting immune cells including T-cells.28 In cancer patients,
BTLA/CD272 is overexpressed in neoplastic cells from
chronic lymphocytic leukemia29 and in melanomas.30 In mel-
anoma patients, BTLA/CD272 is overexpressed in tumor anti-
gen-specific CD8 + T cells. Alike PD-1, BTLA controls T cell
immune functions and thus participates in the immune eva-
sion process.9,31 Concurrent blockade of PD1 and BTLA
release immune exhaustion in melanoma patients tumor-
specific T cells (Fourcade et al., cancer research 2012)
Hence, he inhibition of BTLA with blocking antibodies is
a potential antitumoral therapeutic approach. Finally, together
with sPD-1, sPD-L1, sBTN3A, the soluble form of sBTLA can
be used as an adverse prognostic marker for patients with
unresectable pancreatic cancer.
In conclusion, our study reveals that monitoring the con-
centration of soluble forms of inhibitory immune checkpoints
in plasma can help predict survival in PDAC patients and
suggest that the evolution of soluble checkpoint levels may
reflect therapeutic efficacy. More studies are needed to further
characterize the release of these soluble forms from tumors
and/or stromal cells.
Materials and methods
Patients
Three expert clinical centers (Paoli-Calmettes Institute, Hospital
Nord and Hospital La Timone) from Marseille participated in
this study after receiving ethics review board approval. A total of
59 diagnosed patients with pancreatic adenocarcinoma were
included in this project led by the Paoli-Calmettes Institute
(clinical trial NCT01692873). Consent forms of informed
patients were collected and registered in a central database.
Thirty two samples were used to establish threshold plasma
level for each biomarker of interest (learning cohort). These
thresholds were confirmed in another independent cohort of
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Figure 6. Correlation between plasma levels sPD-1, sPD-L1, sBTLA, sBTN3A1 and pan-sBTN3A) and PDAC patient overall survival from the validation cohort (n = 27).
a to e: A significant inverse correlation was found between sPD-1 (r = −0.59; p = 4.10–3), sPD-L1 (r = −0.6; p = 3.10–4), sBTN3A1 (r = −0.51; p = 4.10–3), pan-sBTN3A
(r = −0.55; p = 3.10–3), sBTLA (r = −0.45; p = 2.10–2) and patient overall survival. The correlation was established using the parametric Pearson correlation coefficient
(r) according to the Gaussian distribution of data (not shown).
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27 patients (validation cohort). All patients were followed from
diagnosis until their death or the last follow-up date. Full anno-
tated clinical characteristics were listed in a central database. To
be noted is that in the validation cohort were included only
patients with locally advanced or metastatic but not patients
with a localized disease, whereas in the validation cohort 55%
of patients presented a localized PDAC. We confirm that the
present study was performed in accordance with REMARK
guidelines and the Declaration of Helsinki.
Determination of soluble PD-L1, PD1, pan-btn3a, BTN3A1
and BTLA concentrations in plasma
ELISAs for pan-BTN3A and BTN3A1 are not commercially
available. Because some discrepancies were observed inmonitor-
ing the three other proteinswhenusing commercial kits obtained
from different sources, we decided to have ELISAs of the 5
markers produced by DYNABIO S.A. (Parc de Luminy,
Marseille France) according to our specifications. These specifi-
cations included (i) verification by tandemmass spectrometry of
the antigen sequence, (ii) optimization of the assay by testing all
combinations of available monoclonal antibodies in capture and
detection, targeting maximal signal/background ratio and sensi-
tivity. Combinations of two ormore antibodies in coating and/or
detectionwerealso tested to improveperformances, (iii) checking
sample compatibility (serum vs plasma, interference of the
matrix), (iv) ensure that assay can be run at room temperature
for easy handling and robustness. The mAbs were made in
D. Olive laboratory immunizing mice with recombinant PD-1,
PD-L-1, BTN3A1, BTN3A and BTLA molecules. The hybrido-
mas were screened for the ability to bind to recombinant PD-1,
PD-L1, BTN3A1, BTN3A and BTLA molecules. They are all of
IgG1 isotype.
All five ELISAs follow the same schedule: All steps are run
at room temperature. Plates are coated overnight with the
antibody selected for capture then washed. Remaining binding
sites are blocked to minimize background. All next steps end
with plate washing. For the PD-L1 assay, all steps are con-
ducted under shaking. Samples to be tested are incubated for
3 h. Then, the biotinylated antibody selected for detection is
incubated for 30 min, followed by incubation for 15 min with
the avidin–peroxidase conjugate. Finally, the substrate TMB is
incubated for 15 min, the reaction stopped with H2SO4 and the
OD read at 450 nm. Concentrations are established by compar-
ison with a range obtained with known concentrations of the
recombinant antigen. All recombinant antigens except PD-L1
(obtained from R&D, cat# 156 B7) were home-synthesized.
Studies comparing concentrations of all 5 markers measured
in serum and plasma from the same blood collection showed
that apparent concentrations in serum were at least three to five
times less than in plasma as shown in supplementary Figure 1.
This observation shows that clotting results in the apparent loss
of a large part of the assayed proteins. Because the mechanism of
such loss is unknown, determination of protein concentrations
in serum might be affected by factors other than the clinical
status of the patient. As consequence, use of serum samples
could be misleading and should be avoided. All samples assayed
in this study were plasmas. We also observed in all 5 ELISAs an
interference of the plasma matrix, which becomes negligible
when plasma samples are diluted at least 1/5. In the present
study, all plasma samples were at least diluted 1/5 before assay.
Details on the five ELISAs are as follows:
a b c
d e
Figure 7. Kaplan–Meier analysis of overall survival in patients from validation cohort with plasma levels above and below the previously determined thresholds of
sPD-1 (a), sPD-L1 (b), sBTLA (c), sBTN3A1 (d) and pan-sBTN3A (e).
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Blood samples
The samples were obtained, under consent, at the time of the
EUS-FNA biopsy procedure or prior to surgery for a patient
with localized and operable tumor. According to inclusion
criteria, all patients were naïve of any chemotherapeutic treat-
ment during blood sampling. Total blood fractions were pro-
cessed within 4 h from the sampling and centrifuged at
2,200 g during 15 min at 4°C in presence of EDTA. The
supernatants (plasma fraction) were aliquoted in cryotubes
and stored at −80°C until processing.
Statistical analysis
Correlation analysis was performed using the Pearson cor-
relation test according to the Gaussian distribution of data.
Overall survival analysis was performed using the Kaplan––
Meier method and log-rank test. Univariate analysis of
survival was performed using the Cox-regression model.
The receiver operating characteristic (ROC) curves were
generated for each marker. The areas under the curves
(AUC) were assessed to evaluate each marker performance
for discriminating short from long-term survivors. SPSS
PASW 23.0 (SPSS Inc. Chicago, IL, USA) software was
used for regression analysis. ROC curves were generated
using the MedCalc software for Windows, version 18.2.1
(MedCalc Software, Ostend, Belgium). GraphPad Prism
5.01 (GraphPad software Inc. La Jolla, CA, USA) was used
for correlation and Kaplan-Meier survival analysis.
P values < 0.05 were considered significant.
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